Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and a corporate update.
Investors can access the live webcast and archived replay via the Investors section of the company website at www.kuraoncology.com.
Details
News Market Reaction – KURA
On Feb 26, the day this news came out, KURA closed 1.05% above the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Earnings date
- March 5, 2026
- Planned release of Q4 and full-year 2025 results
- Earnings call time
- 8:00 a.m. ET
- Scheduled conference call to discuss results
- Webcast time
- 5:00 a.m. PT
- Corresponding webcast timing for investors
- Current price
- $8.56
- Price before earnings-date announcement
- Price change 24h
- 2.15%
- Move ahead of earnings date news
- 52-week high
- $12.49
- Pre-news 52-week range upper bound
- 52-week low
- $5.41
- Pre-news 52-week range lower bound
- Market cap
- $729,206,801
- Equity value prior to earnings-date announcement
Historical Context
-
Participation in three March 2026 healthcare investor conferences.
-
Inducement grants totaling 69,750 options to new employees.
-
FDA approval, KOMZIFTI launch and preliminary revenue and cash update.
-
Option grants to new employees under 2023 Inducement Option Plan.
-
Strong KOMZIFTI combo data in NPM1-mutated and KMT2A-rearranged AML.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.